Rare Pediatric Disease designation
Capricor Gains 11% as FDA Pushes Deramiocel Decision to Nov
A three-month delay is not usually something a stock rallies on. Capricor Therapeutics gained 11% anyway. The company’s Duchenne muscular dystrophy therapy just got a longer FDA review instead of a decision, and investors treated the extra scrutiny as a sign the door stayed open rather than a rejection in slow motion. Capricor Gains 11%…
